Skip to main content

Month: September 2021

HEXO Achieves Carbon Neutrality

Company offsets 25,965 tonnes of carbon and the equivalent of 3.55 million plastic bottles OTTAWA, Sept. 16, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced the Company had achieved its goal to become carbon neutral by September 2021, offsetting 100% of its 2020 operational carbon emissions in addition to the personal emissions of its 1,200 employees*. In June of 2021, HEXO embarked on a mission to counteract its carbon footprint, through a partnership with Offsetters, a Vancouver-based organization that supports renewable energy and forest carbon projects across the world. As a leading cannabis player in Canada, on the path to becoming one of the top three global cannabis products companies, it was important for HEXO’s offset investments to have a global reach. At home in Canada,...

Continue reading

CNH Industrial joins 5G Open Innovation Lab

London, September 16, 2021 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announced today that it has joined the 5G Open Innovation Lab (“5GOILab”), a global applied innovation ecosystem for corporations, academia and government institutions working on developing 5G technologies, as corporate partner. “We are incredibly excited to join the 5G Open Innovation Lab as their first industry partner for precision agriculture. This unique platform enables us to collaborate with innovative startups and engage with bright minds working on transformative 5G technologies in the agricultural space,” said Scott Wine, Chief Executive Officer, CNH Industrial. “This partnership underscores our commitment to aggressively enhance our precision farming portfolio through the development of new connected digital technologies that allow our customers...

Continue reading

Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021

BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The findings focus on the exploration of genomics amongst the Chinese population, and provide important insights for clinical pathology classification, targeted therapy and immunotherapy strategies, and the clinical management of hereditary colorectal cancer. The research adopted Genetron’s proprietary technology such as the One-Step Seq Method,...

Continue reading

UTStarcom signed a strategic cooperation agreement with Zhongrui Technology

HANGZHOU, China, Sept. 16, 2021 (GLOBE NEWSWIRE) — UTStarcom (“UTStarcom” or the “Company”) (NASDAQ:UTSI), a global telecommunications infrastructure provider, today announced that UTStarcom Communications Co., Ltd. signed a strategic cooperation agreement with China Comservice Zhongrui Technology Co., Ltd. (“Zhongrui Technology”) on September 8, 2021. The strategic cooperation between the two companies will focus on the development and production of software and hardware products of UTStarcom and Zhongrui Technology in the fields of blockchain, Internet of Things (IoT), cloud computing, big data, artificial intelligence, 5G + Industrial Internet, information security and others. Initial focus is going to be on the blockchain and 5G access/IoT devices and applications. The cooperation agreement creates a foundation...

Continue reading

Transfer of Registered Office Approved by the Extraordinary General Meeting of Shareholders of Multitude SE

Transfer of Registered Office Approved by the Extraordinary General Meeting of Shareholders of Multitude SE Helsinki, 16 September 2021 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or “Company”). DECISIONS OF MULTITUDE SE’S EXTRAORDINARY GENERAL MEETING Multitude SE held its Extraordinary General Meeting today under special arrangements and the meeting made the following resolutions. TRANSFER OF THE REGISTERED OFFICE OF MULTITUDE SE FROM HELSINKI, FINLAND TO HAMBURG, GERMANY Multitude SE has on 9 July 2021 announced that the Board of Directors had decided to approve a transfer proposal for the transfer of the registered office of Multitude SE from Helsinki, Finland to Hamburg, Germany (“Transfer”) in accordance with the Council Regulation (EC) No 2157/2001 of 8 October 2001 on the Statute for a European Company (SE) (“Transfer...

Continue reading

Chindata Group Participates in China’s First Green Power Transaction

BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) — Chindata Group (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced that it has recently participated in China’s first nationwide green power transaction, and completed a procurement of 100 million kilowatt-hours (kWh). Such volume represents around 1.26% of the overall transaction and is expected to directly reduce greenhouse gas emissions by approximately 94,000 tons of carbon dioxide equivalent. According to public data, a total of 259 domestic Chinese entities participated in this green power transaction, with a total transaction volume of 7.935 billion kWh. Following the announcement of China’s goals of reaching peak carbon emissions by 2030 and carbon neutrality by 2060, a series of policies were introduced,...

Continue reading

MISTRAS Group to Hold a Live Q&A Fireside Chat at the Sidoti Virtual Investor Conference

PRINCETON JUNCTION, N.J., Sept. 16, 2021 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE) – a leading “one source” global provider of technology-enabled asset protection solutions used to maximize the uptime and safety of critical energy, industrial, and public infrastructure – announced today that Dennis Bertolotti, Chief Executive Officer, and Edward Prajzner, Chief Financial Officer, will participate in investor meetings and a fireside chat at the Sidoti Virtual Investor Conference. The live presentation in a Question & Answer format will be on September 23, 2021, beginning at 9:15 AM Eastern. You may access this discussion at: https://sidoti.zoom.us/webinar/register/WN_InPLq397TWumFYFQU7PAKA One-on-one meetings will be scheduled for September 22nd and 23rd. Investors interested in meeting with management should contact...

Continue reading

Share Buyback Transaction Details September 9 – September 15, 2021

Share Buyback Transaction Details September 9 – September 15, 2021 September 16, 2021 – Wolters Kluwer today reports that it has repurchased 61,930 of its own ordinary shares in the period from September 9, 2021, up to and including September 15, 2021, for €6.0 million and at an average share price of €96.52. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2021 to date 3,459,114 262.0 75.73For the period starting August 5, 2021, up to and including November 1, 2021,...

Continue reading

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Patient selection using DRP® score of 50% resulted in a median survival of 15.0 month Patient selection using DRP® score of 67% resulted in a median survival of 20.6 monthsPress Release Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which will be included in a poster presentation at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress taking place from September 16 until September 21, 2021. The poster displays how the RCC patients selected with the Dovitinib DRP® companion diagnostic (i.e., those who had a DRP® score above 50%) had a median survival of 15.0 months (N=49), compared to a median...

Continue reading

Investor event: Presentation of Arco Vara’s activities and share issue

On September 30, 2021 at 6:30 PM Arco Vara AS will hold a presentation of Arco Vara’s activities and the offer document of the share issue for current and future investors. The formal part will be followed by a free-form meeting with the company management. The event will take place at KÄRBES Kitchen&Bar, Telliskivi 60a, Tallinn. Participation is free of charge on the basis of pre-registration (maximum 150 people). To register, send an e-mail to info@arcovara.com. When you come to the event, you will need to present an immunization certificate or a Covid test certificate up to 48 hours old. Further information and registration info@arcovara.com. Lilian TaliAssistant to the Management Boardinfo@arcovara.com +372 614 4630

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.